Kalvista Pharmaceuticals Inc (KALV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kalvista Pharmaceuticals Inc stock (KALV) is currently trading at $17.14. Kalvista Pharmaceuticals Inc PS ratio (Price-to-Sales) is 602.59. Analyst consensus price target for KALV is $34.00. WallStSmart rates KALV as Sell.
- KALV PE ratio analysis and historical PE chart
- KALV PS ratio (Price-to-Sales) history and trend
- KALV intrinsic value — DCF, Graham Number, EPV models
- KALV stock price prediction 2025 2026 2027 2028 2029 2030
- KALV fair value vs current price
- KALV insider transactions and insider buying
- Is KALV undervalued or overvalued?
- Kalvista Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- KALV Piotroski F-Score and Altman Z-Score
- KALV analyst price target and Smart Rating
Kalvista Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Kalvista Pharmaceuticals Inc (KALV) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Kalvista Pharmaceuticals Inc (KALV) Key Strengths (2)
Revenue surging 30.70% year-over-year
136.82% of shares held by major funds and institutions
Supporting Valuation Data
Kalvista Pharmaceuticals Inc (KALV) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 602.6x annual revenue
Very expensive at 50.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Kalvista Pharmaceuticals Inc (KALV) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 30.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (602.59), Price/Book (50.55) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -190.20%, Operating Margin at -336.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -190.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 30.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KALV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KALV's Price-to-Sales ratio of 602.59x trades 145% above its historical average of 245.48x (95th percentile), historically expensive. The current valuation is 90% below its historical high of 6309.54x set in Dec 2015, and 5423% above its historical low of 10.91x in Sep 2016. Over the past 12 months, the PS ratio has expanded from ~47.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Kalvista Pharmaceuticals Inc (KALV) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Kalvista Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1M with 31% growth year-over-year.
Key Findings
Revenue growing at 31% YoY, reaching 1M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 841% of revenue (12M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -33M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Debt-to-equity ratio of 8.80 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Growth sustainability: can Kalvista Pharmaceuticals Inc maintain 31%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Kalvista Pharmaceuticals Inc.
Bottom Line
Kalvista Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 31% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(41 last 3 months)
| Insider | Type | Shares |
|---|---|---|
PALLEIKO, BENJAMIN L Director, CHIEF EXECUTIVE OFFICER | Sell | -6,693 |
| Insider | Type | Shares |
|---|---|---|
PALLEIKO, BENJAMIN L Director, CHIEF EXECUTIVE OFFICER | Sell | -3,354 |
Data sourced from SEC Form 4 filings
Last updated: 11:32:37 AM
About Kalvista Pharmaceuticals Inc(KALV)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.